Pathogenesis of Bullous Pemphigoid

Immunology and Allergy Clinics of North America

Volumn 32, Issue 2, 2012, Pages 207-215

  Ujiie, Hideyuki ^a   Nishie, Wataru ^a   Shimizu, Hiroshi ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Animal model; Bullous pemphigoid; IgE autoantibody; NC16A; Pathogenesis; Type XVII collagen

Indexed keywords

AUTOANTIBODY; COLLAGEN TYPE 17; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

BLISTER; BULLOUS PEMPHIGOID; CD4+ T LYMPHOCYTE; COMPLEMENT ACTIVATION; DISEASE ACTIVITY; EROSION; HUMAN; IMMUNOGLOBULIN DEPOSITION; INFLAMMATORY INFILTRATE; MAST CELL DEGRANULATION; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REMISSION; REVIEW; SKIN FRAGILITY; URTICARIA;

ADOPTIVE TRANSFER; ANIMALS; AUTOANTIBODIES; AUTOANTIGENS; BLISTER; CD4-POSITIVE T-LYMPHOCYTES; COMPLEMENT ACTIVATION; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; MICE; MICE, KNOCKOUT; NON-FIBRILLAR COLLAGENS; PEMPHIGOID, BULLOUS;

EID: 84860461612     PISSN: 08898561     EISSN: 15578607     Source Type: Journal    
DOI: 10.1016/j.iac.2012.04.001     Document Type: Review

References (45)

1. Bernard P., Vaillant L., Labeille B., et al. Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions. Bullous Diseases French Study Group. Arch Dermatol 1995, 13:48-52.
2. Marazza G., Pham H.C., Scharer L., et al. Incidence of bullous pemphigoid and pemphigus in Switzerland: a 2-year prospective study. Br J Dermatol 2009, 161:861-868.
3. Stanley J.R., Hawley-Nelson P., Yuspa S.H., et al. Characterization of bullous pemphigoid antigen: a unique basement membrane protein of stratified squamous epithelia. Cell 1981, 24:897-903.
4. Stanley J.R., Tanaka T., Mueller S., et al. Isolation of complementary DNA for bullous pemphigoid antigen by use of patients' autoantibodies. J Clin Invest 1988, 82:1864-1870.
5. Guo L., Degenstein L., Dowling J., et al. Gene targeting of BPAG1: abnormalities in mechanical strength and cell migration in stratified epithelia and neurologic degeneration. Cell 1995, 81:233-243.
6. Hall R.P., Murray J.C., McCord M.M., et al. Rabbits immunized with a peptide encoded for by the 230-kD bullous pemphigoid antigen cDNA develop an enhanced inflammatory response to UVB irradiation: a potential animal model for bullous pemphigoid. J Invest Dermatol 1993, 101:9-14.
7. Kiss M., Husz S., Janossy T., et al. Experimental bullous pemphigoid generated in mice with an antigenic epitope of the human hemidesmosomal protein BP230. J Autoimmun 2005, 24:1-10.
8. Diaz L.A., Ratrie H., Saunders W.S., et al. Isolation of a human epidermal cDNA corresponding to the 180-kD autoantigen recognized by bullous pemphigoid and herpes gestationis sera. Immunolocalization of this protein to the hemidesmosome. J Clin Invest 1990, 86:1088-1094.
9. Bedane C., McMillan J.R., Balding S.D., et al. Bullous pemphigoid and cicatricial pemphigoid autoantibodies react with ultrastructurally separable epitopes on the BP180 ectodomain: evidence that BP180 spans the lamina lucida. J Invest Dermatol 1997, 108:901-907.
10. Ishiko A., Shimizu H., Kikuchi A., et al. Human autoantibodies against the 230-kD bullous pemphigoid antigen (BPAG1) bind only to the intracellular domain of the hemidesmosome, whereas those against the 180-kD bullous pemphigoid antigen (BPAG2) bind along the plasma membrane of the hemidesmosome in normal human and swine skin. J Clin Invest 1993, 91:1608-1615.
11. Giudice G.J., Emery D.J., Diaz L.A. Cloning and primary structural analysis of the bullous pemphigoid autoantigen BP180. J Invest Dermatol 1992, 99:243-250.
12. Giudice G.J., Emery D.J., Zelickson B.D., et al. Bullous pemphigoid and herpes gestationis autoantibodies recognize a common non-collagenous site on the BP180 ectodomain. J Immunol 1993, 151:5742-5750.
13. Zillikens D., Rose P.A., Balding S.D., et al. Tight clustering of extracellular BP180 epitopes recognized by bullous pemphigoid autoantibodies. J Invest Dermatol 1997, 109:573-579.
14. Franzke C.W., Bruckner-Tuderman L., Blobel C.P. Shedding of collagen XVII/BP180 in skin depends on both ADAM10 and ADAM9. J Biol Chem 2009, 284:23386-23396.
15. Zillikens D., Mascaro J.M., Rose P.A., et al. A highly sensitive enzyme-linked immunosorbent assay for the detection of circulating anti-BP180 autoantibodies in patients with bullous pemphigoid. J Invest Dermatol 1997, 109:679-683.
16. Haase C., Budinger L., Borradori L., et al. Detection of IgG autoantibodies in the sera of patients with bullous and gestational pemphigoid: ELISA studies utilizing a baculovirus-encoded form of bullous pemphigoid antigen 2. J Invest Dermatol 1998, 110:282-286.
17. Hofmann S., Thoma-Uszynski S., Hunziker T., et al. Severity and phenotype of bullous pemphigoid relate to autoantibody profile against the NH2- and COOH-terminal regions of the BP180 ectodomain. J Invest Dermatol 2002, 119:1065-1073.
18. Di Zenzo G., Grosso F., Terracina M., et al. Characterization of the anti-BP180 autoantibody reactivity profile and epitope mapping in bullous pemphigoid patients. J Invest Dermatol 2004, 122:103-110.
19. Di Zenzo G., Calabresi V., Olasz E.B., et al. Sequential intramolecular epitope spreading of humoral responses to human BPAG2 in a transgenic model. J Invest Dermatol 2009, 130:1040-1047.
20. Nishie W., Lamer S., Schlosser A., et al. Ectodomain shedding generates Neoepitopes on collagen XVII, the major autoantigen for bullous pemphigoid. J Immunol 2010, 185:4938-4947.
21. Schumann H., Baetge J., Tasanen K., et al. The shed ectodomain of collagen XVII/BP180 is targeted by autoantibodies in different blistering skin diseases. Am J Pathol 2000, 156:685-695.
22. Hofmann S.C., Voith U., Schonau V., et al. Plasmin plays a role in the in vitro generation of the linear IgA dermatosis antigen LADB97. J Invest Dermatol 2009, 129:1730-1739.
23. Sitaru C., Schmidt E., Petermann S., et al. Autoantibodies to bullous pemphigoid antigen 180 induce dermal-epidermal separation in cryosections of human skin. J Invest Dermatol 2002, 118:664-671.
24. Iwata H., Kamio N., Aoyama Y., et al. IgG from patients with bullous pemphigoid depletes cultured keratinocytes of the 180-kDa bullous pemphigoid antigen (type XVII collagen) and weakens cell attachment. J Invest Dermatol 2009, 129:919-926.
25. Liu Z., Diaz L.A., Troy J.L., et al. A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180. J Clin Invest 1993, 92:2480-2488.
26. Liu Z., Giudice G.J., Swartz S.J., et al. The role of complement in experimental bullous pemphigoid. J Clin Invest 1995, 95:1539-1544.
27. Chen R., Ning G., Zhao M.L., et al. Mast cells play a key role in neutrophil recruitment in experimental bullous pemphigoid. J Clin Invest 2001, 108:1151-1158.
28. Liu Z., Giudice G.J., Zhou X., et al. A major role for neutrophils in experimental bullous pemphigoid. J Clin Invest 1997, 100:1256-1263.
29. Liu Z., Shapiro S.D., Zhou X., et al. A critical role for neutrophil elastase in experimental bullous pemphigoid. J Clin Invest 2000, 105:113-123.
30. Olasz E.B., Roh J., Yee C.L., et al. Human bullous pemphigoid antigen 2 transgenic skin elicits specific IgG in wild-type mice. J Invest Dermatol 2007, 127:2807-2817.
31. Nishie W., Sawamura D., Goto M., et al. Humanization of autoantigen. Nat Med 2007, 13:378-383.
32. Wang G., Ujiie H., Shibaki A., et al. Blockade of autoantibody-initiated tissue damage by using recombinant fab antibody fragments against pathogenic autoantigen. Am J Pathol 2010, 176:914-925.
33. Li Q., Ujiie H., Shibaki A., et al. Human IgG1 monoclonal antibody against human collagen L17 noncollagenous 16A domain induces blisters via complement activation in experimental bullous pemphigoid model. J Immunol 2010, 185:7746-7755.
34. Ujiie H., Shibaki A., Nishie W., et al. A novel active mouse model for bullous pemphigoid targeting humanized pathogenic antigen. J Immunol 2010, 184:2166-2174.
35. Budinger L., Borradori L., Yee C., et al. Identification and characterization of autoreactive T cell responses to bullous pemphigoid antigen 2 in patients and healthy controls. J Clin Invest 1998, 102:2082-2089.
36. Lin M.S., Fu C.L., Giudice G.J., et al. Epitopes targeted by bullous pemphigoid T lymphocytes and autoantibodies map to the same sites on the bullous pemphigoid 180 ectodomain. J Invest Dermatol 2000, 115:955-961.
37. Thoma-Uszynski S., Uter W., Schwietzke S., et al. Autoreactive T and B cells from bullous pemphigoid (BP) patients recognize epitopes clustered in distinct regions of BP180 and BP230. J Immunol 2006, 176:2015-2023.
38. Delgado J.C., Turbay D., Yunis E.J., et al. A common major histocompatibility complex class II allele HLA-DQB1* 0301 is present in clinical variants of pemphigoid. Proc Natl Acad Sci U S A 1996, 93:8569-8571.
39. Provost T.T., Tomasi T.B. Immunopathology of bullous pemphigoid. Basement membrane deposition of IgE, alternate pathway components and fibrin. Clin Exp Immunol 1974, 18:193-200.
40. Friedmann P.S. Assessment of urticaria and angio-oedema. Clin Exp Allergy 1999, 29(Suppl 3):109-112.
41. Dimson O.G., Giudice G.J., Fu C.L., et al. Identification of a potential effector function for IgE autoantibodies in the organ-specific autoimmune disease bullous pemphigoid. J Invest Dermatol 2003, 120:784-788.
42. Iwata Y., Komura K., Kodera M., et al. Correlation of IgE autoantibody to BP180 with a severe form of bullous pemphigoid. Arch Dermatol 2008, 144:41-48.
43. Zone J.J., Taylor T., Hull C., et al. IgE basement membrane zone antibodies induce eosinophil infiltration and histological blisters in engrafted human skin on SCID mice. J Invest Dermatol 2007, 127:1167-1174.
44. Fairley J.A., Burnett C.T., Fu C.L., et al. A pathogenic role for IgE in autoimmunity: bullous pemphigoid IgE reproduces the early phase of lesion development in human skin grafted to nu/nu mice. J Invest Dermatol 2007, 127:2605-2611.
45. Fairley J.A., Baum C.L., Brandt D.S., et al. Pathogenicity of IgE in autoimmunity: successful treatment of bullous pemphigoid with omalizumab. J Allergy Clin Immunol 2009, 123:704-705.